Navigation Links
NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
Date:2/11/2008

Clinical Poster Presented at Annual Meeting of the American Academy of

Dermatology

PRINCETON, N.J., Feb. 11 /PRNewswire/ -- NeoStrata today released new clinical data that demonstrates significant benefits in combining microdermabrasion procedures with free acid glycolic acid peels plus bionic/poly-hydroxy acid (PHA) at-home products in improving the appearance and texture of facial skin. The data were highlighted in the Poster Session at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio.

"Microdermabrasion and glycolic acid peels are popular aesthetic procedures for the treatment of photo-damaged skin and acne because they act to exfoliate the epidermis and stimulate cell renewal," said Barbara Green, Vice President for Technology and Clinical Affairs at NeoStrata. "Our research shows there is significant benefit in skin tone, texture and appearance when microdermabrasion is supplemented with glycolic acid peels in a bi-weekly protocol supported by appropriate at-home daily use of bionic and PHA products."

A group of 10 patients applied a 10 percent alpha-hydroxy acid (AHA) cream each evening for two weeks prior to in-office procedures. This conditioning phase served to acclimate the skin to AHAs. Free acid glycolic peels and microdermabrasion treatments were performed alternately every two weeks for a total of four glycolic acid peels and four microdermabrasions over 16 weeks. Patients were given anti-oxidant-rich Bionic/PHA creams post-procedurally, when skin may be sensitive, to calm irritation, hydrate skin and help repair skin barrier function. Patients were also given a collection of bionic/PHA products for at-home use in between procedures, including a cleanser, moisturizer/sunscreen and night cream. The products provided anti-oxidant effects, redness reduction and barrier strengthening.

According to Ms. Green, 100 percent of subjects perceived early benefits after one series of treatments, enhancing patient compliance and commitment to the full protocol. Physicians used a gradual increase in both peel concentration and microdermabrasion vacuum pressure, as tolerated. After the full series of treatments, patients noticed marked improvement in clarity, fine lines and coarse wrinkling. Patients also recorded dramatic improvement in skin firmness and brightness/luminosity.

"The combination approach validates our belief in the benefits of complementary procedures focusing on accelerated exfoliation and cellular renewal -- supplemented with a skin care regimen based on effective yet gentle bionic/PHA technology," said Ms. Green. "An integrated, targeted regimen can provide effective benefits to the overall appearance and texture of skin without the downtime of more invasive cosmetic procedures."

About NeoStrata

The NeoStrata Company, located in Princeton, NJ, develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies and spas.


'/>"/>
SOURCE The NeoStrata Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The NeoStrata Company Appoints a New Vice President of Operations
2. NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures
3. Radiologists encouraged to look beyond cancer for clinically unseen diseases
4. Clinical depression linked to abnormal emotional brain circuits
5. Preclinical study suggests organ-transplant drug may aid in lupus fight
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Good Clinical Practice Journal Awards: Winners Announced
8. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
9. Study Questions Dead-End Cancer Clinical Trials
10. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
11. Clinical trials present better alternatives for dialysis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... With over ... to walk, the demand for a sustainable product to aid in the rehabilitation process ... aid in the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. ... from leading advocates, associations and industry leaders such as Bioness. , As ...
(Date:5/27/2016)... ... , ... Beleza Medspa has initiated a new program to assist ... first time that Coolsculpting is being used for for more than just cosmetic purposes. ... meet the prescribed body-fat standard, measured by the circumference-based tape method. The tape-test ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 Amarantus BioScience ... on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today ... be presenting at two upcoming investor conferences: SeeThru ... Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
Breaking Medicine Technology: